Good MorningEquity markets ended the last week on a high note despite weaker than expected jobs data. The non-farm payrolls report showed less than half the expected number of new jobs were created despite record-setting levels of job openings. With the number of job openings only expected to rise as we enter the holiday shopping season it looks like the major retailers are going to be scrambling for employees.
This will be a light week for trading with the Labor Day holiday cutting the week short. Other than that, there is little for the market to get excited about except the Fed’s Beige Book and the PPI data on Friday. Both the PPI data and Beige Book are expected to show the continued impacts of inflation and help drive the Fed closer to tapering and the eventual onset of tightening.
Featured: Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad) 
|
Finance | | Subprime auto financing specialist Credit Acceptance Corp. (NASDAQ: CACC) raced 15.74% last week.
The upside action came on news that the company reached a $27.2 million settlement with Massachusetts to resolve claims that it misled its investors and made high-interest loans to borrowers who lacked... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Healthcare | | After forming a base for nearly six months, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) broke out last week, continuing an uptrend that began following the company’s second-quarter earnings report in July.
It marked the third consecutive quarter of accelerating ea... Read the Full Story |
|
Markets | | iGaming platform Golden Nugget Online Gaming (NASDAQ: GNOG) stock recently exploded higher on a definitive acquisition agreement from Draft Kings (NASDAQ: DKNG) in an all stock deal. The transaction is expected to close in Q1 2022. The transaction is a fixed ratio of 0.365 shares of Draft Kings stoc... Read the Full Story |
|
From Our Partners | | TradeSmith CEO Keith Kaplan warns that AI's rapid rise has a dark side, threatening American jobs and livelihoods. He says now is the time to prepare before September 30th.
TradeSmith has invested $17 million in AI tools and built a platform used by 180,000 traders worldwide. One user, Stephen, credits it with building a $2.95 million retirement portfolio. | | See where Kaplan says to move your money before September 30th |
|
Finance | | Buy now and pay later purchase financing provider Affirm (NASDAQ: AFRM) stock has been on a frenetic rally as its Amazon (NASDAQ: AMZN) partnership could be a gamechanger. The flexible payments provider is a leader in the buy-it-now and pay in installments category. The Amazon partnership will enabl... Read the Full Story |
|
Markets | |
Have you decided you're mentally ready to retire?
How about financially? You might already know someone who decides they want to retire, tells all their friends, family and neighbors, then looks into the "financial stuff."
A financial advisor friend I know once said people do it all the time &m... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | | It’s always tricky trying to figure out the best way to position ahead of a company’s earnings report, as these binary events can lead to big moves both up and down for the price of a stock. While it might be tempting to add shares ahead of a release, waiting until after a company report... Read the Full Story |
|
Consumer Discretionary | | It’s been nothing short of fascinating to see all of the changes that have occurred in the real estate market since the beginning of the pandemic. Last year, the unfortunate circumstances led to one of the hottest home-buying sprees of all time and created a feeding frenzy of buyers trying to ... Read the Full Story |
|
Finance | | It’s easy to find reasons to invest in companies that are based in the United States, as our financial markets contain some of the most innovative and financially secure businesses in the world. With that said, investors are doing themselves a major disservice if they are only focused on addin... Read the Full Story |
|
Consumer Discretionary | |
Fairly Valued Five Below Gets Cheaper
Shares of Five Below (NASDAQ: FIVE) entered a correction two weeks ago when Morgan Stanley downgraded the stock to Equal Weight from Over Weight. The reasoning was simple and shouldn’t have sparked the correction it did. According to Morgan Stanley, th... Read the Full Story |
|
Communication Services | | Live entertainment operator Live Nation (NYSE: LYV) stock has been a strong 2021 performer as the reopening gets underway with the acceleration of COVID vaccinations. Concerts and live performances were an epicenter segment during the COVID-19 pandemic as capacity restrictions and stay-at-home manda... Read the Full Story |
|
The Early Bird Stock Of The Day Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. | | View Today's Stock Pick |
|
